Replies to post #600345 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

The objective third party that vets the MOA will be the regulator. No doubt the proteomic analysis are included in regulatory applications.

Why else would they pay a firm to do this work now, when they don't have a lot of cash, unless it was necessary for approval which we know are their primary goal not publishing another journal?

Yet instead of thinking about context all you can do are raising moot points about a peer reviewed journal.

Some like attention.

Others get work done.

[skitahoe]

OJ,

I agree with you and in fact I asked the question shortly after his presentation if the T-cell related materials he spoke of had been presented previously at one of the appearance by Dr. Liau or others that I hadn't seen. No one answered.

I don't doubt that anything he said wasn't true, but at some point it should be used in a peer reviewed presentation. Frankly it's unusual for a company to provide detailed scientific information that hasn't been peer reviewed. Perhaps when Dr. Liau appears in behalf of the company it will be presented and constitute peer review, though I'm uncertain that's the case.

Frankly it's hard to believe that this wasn't included in the Journal if it was known at the time, I can only guess that it really hadn't been discovered until more recently. Remember it's contractors who put everything from the trial together, it's very possible that they didn't delve into T-cells until many other things were completed, and perhaps they found much more than they ever anticipated.

Gary